Analysts Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $11.81

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.8125.

Several research firms recently issued reports on OPRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of OptimizeRx in a report on Saturday, September 27th. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a research note on Friday, August 8th. Stifel Nicolaus lifted their price objective on OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. JMP Securities lifted their price objective on OptimizeRx from $14.00 to $20.00 and gave the stock a “market outperform” rating in a research note on Monday, August 11th. Finally, Zacks Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 5th.

Insiders Place Their Bets

In other OptimizeRx news, CEO Stephen L. Silvestro sold 1,620 shares of OptimizeRx stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares in the company, valued at approximately $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Patrick D. Spangler sold 11,120 shares of OptimizeRx stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $17.49, for a total value of $194,488.80. Following the transaction, the director owned 44,215 shares in the company, valued at approximately $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its position in OptimizeRx by 54.5% in the fourth quarter. Bank of America Corp DE now owns 73,934 shares of the company’s stock valued at $359,000 after purchasing an additional 26,093 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of OptimizeRx by 298.8% during the 4th quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock worth $203,000 after buying an additional 31,252 shares during the last quarter. GAMMA Investing LLC acquired a new position in shares of OptimizeRx during the 1st quarter worth about $33,000. Rhumbline Advisers raised its holdings in OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after acquiring an additional 2,636 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in OptimizeRx by 47.1% during the first quarter. Janney Montgomery Scott LLC now owns 124,751 shares of the company’s stock valued at $1,080,000 after purchasing an additional 39,969 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Price Performance

OptimizeRx stock opened at $17.95 on Friday. The business’s 50-day simple moving average is $17.12 and its 200 day simple moving average is $13.32. The stock has a market cap of $333.33 million, a price-to-earnings ratio of -33.24 and a beta of 1.25. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $20.69. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.21.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.